BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 9450813)

  • 1. Megakaryocyte progenitors derived from bone marrow or G-CSF-mobilized peripheral blood CD34 cells show a distinct phenotype and responsiveness to interleukin-3 (IL-3) and PEG-recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF).
    Catani L; Gugliotta L; Campanini E; Mangianti S; Gibellini D; Baravelli S; Vianelli N; Lemoli RM; Tura S
    Br J Haematol; 1998 Jan; 100(1):207-18. PubMed ID: 9450813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood.
    Gehling UM; Ryder JW; Hogan CJ; Hami L; McNiece I; Franklin W; Williams S; Helm K; King J; Shpall EJ
    Exp Hematol; 1997 Oct; 25(11):1125-39. PubMed ID: 9328449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic effects of pegylated recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor on mobilization of hematopoietic progenitor and stem cells with long-term repopulating ability into peripheral blood in mice.
    Honda K; Takenaka K; Shinagawa K; Ishimaru F; Ikeda K; Niiya K; Harada M
    Bone Marrow Transplant; 2001 Aug; 28(4):329-34. PubMed ID: 11571503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates.
    Harker LA; Marzec UM; Hunt P; Kelly AB; Tomer A; Cheung E; Hanson SR; Stead RB
    Blood; 1996 Jul; 88(2):511-21. PubMed ID: 8695799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane.
    Janowska-Wieczorek A; Marquez LA; Nabholtz JM; Cabuhat ML; MontaƱo J; Chang H; Rozmus J; Russell JA; Edwards DR; Turner AR
    Blood; 1999 May; 93(10):3379-90. PubMed ID: 10233890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cycling status of CD34+ cells mobilized into peripheral blood of healthy donors by recombinant human granulocyte colony-stimulating factor.
    Lemoli RM; Tafuri A; Fortuna A; Petrucci MT; Ricciardi MR; Catani L; Rondelli D; Fogli M; Leopardi G; Ariola C; Tura S
    Blood; 1997 Feb; 89(4):1189-96. PubMed ID: 9028941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of defective megakaryocytic development in patients with myelodysplastic syndromes.
    Hofmann WK; Kalina U; Wagner S; Seipelt G; Ries C; Hoelzer D; Ottmann OG
    Exp Hematol; 1999 Mar; 27(3):395-400. PubMed ID: 10089900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor.
    Harker LA; Marzec UM; Kelly AB; Cheung E; Tomer A; Nichol JL; Hanson SR; Stead RB
    Blood; 1997 Jan; 89(1):155-65. PubMed ID: 8978288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multilineage hematopoietic recovery by a single injection of pegylated recombinant human megakaryocyte growth and development factor in myelosuppressed mice.
    Shibuya K; Akahori H; Takahashi K; Tahara E; Kato T; Miyazaki H
    Blood; 1998 Jan; 91(1):37-45. PubMed ID: 9414267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GpIIb/IIIa+ subpopulation of rat megakaryocyte progenitor cells exhibits high responsiveness to human thrombopoietin.
    Kato T; Horie K; Hagiwara T; Maeda E; Tsumura H; Ohashi H; Miyazaki H
    Exp Hematol; 1996 Aug; 24(10):1209-14. PubMed ID: 8765496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of megakaryopoiesis in vitro of paired peripheral blood progenitor cells and bone marrow harvested during remission in patients with acute myeloid leukaemia.
    Briggs M; Adams JA; Brereton ML; Burgess R; Hyde K; Lenehan H; Yin JA
    Br J Haematol; 2001 Dec; 115(3):563-8. PubMed ID: 11736936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological characterization of CD34+ cells mobilized into peripheral blood.
    Lemoli RM; Tafuri A; Fortuna A; Catani L; Rondelli D; Ratta M; Tura S
    Bone Marrow Transplant; 1998 Dec; 22 Suppl 5():S47-50. PubMed ID: 9989890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Megakaryocyte growth and development factor accelerates platelet recovery in peripheral blood progenitor cell transplant recipients.
    Molineux G; Hartley C; McElroy P; McCrea C; McNiece IK
    Blood; 1996 Jul; 88(1):366-76. PubMed ID: 8704197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Megakaryocyte growth and development factor stimulates enhanced platelet recovery in mice after bone marrow transplantation.
    Molineux G; Hartley CA; McElroy P; McCrea C; McNiece IK
    Blood; 1996 Aug; 88(4):1509-14. PubMed ID: 8695873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Megakaryopoiesis in vitro in myelodysplastic syndromes and acute myeloid leukaemia: effect of pegylated recombinant human megakaryocyte growth and development factor in combination with other growth factors.
    Liu Yin JA; Adams JA; Brereton ML; Hann A; Harrison BD; Briggs M
    Br J Haematol; 2000 Mar; 108(4):743-6. PubMed ID: 10792278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The in vitro effect of pegylated recombinant human megakaryocyte growth and development factor (PEG rHuMGDF) on megakaryopoiesis in normal subjects and patients with myelodysplasia and acute myeloid leukaemia.
    Adams JA; Liu Yin JA; Brereton ML; Briggs M; Burgess R; Hyde K
    Br J Haematol; 1997 Oct; 99(1):139-46. PubMed ID: 9359514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expansion of megakaryocyte progenitors from CD34+-enriched mobilized peripheral blood stem cells is inhibited by Flt3-L.
    Case J; Hicks C; Trickett A; Kwan YL; Manoharan A
    J Interferon Cytokine Res; 2006 Feb; 26(2):76-82. PubMed ID: 16487027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of the phenotype and proliferative capacity of peripheral blood (PB) CD34+ cells mobilized by four different protocols and those of steady-phase PB and bone marrow CD34+ cells.
    To LB; Haylock DN; Dowse T; Simmons PJ; Trimboli S; Ashman LK; Juttner CA
    Blood; 1994 Nov; 84(9):2930-9. PubMed ID: 7524760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined use of growth factors to stimulate the proliferation of hematopoietic progenitor cells after autologous bone marrow transplantation for lymphoma patients.
    Lemoli RM; Fortuna A; Fogli M; Rosti G; Gherlinzoni F; Visani G; Catani L; Gozzetti A; Tura S
    Acta Haematol; 1996; 95(3-4):164-70. PubMed ID: 8677737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.